Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
02:31pm, Monday, 02'nd Dec 2024
NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such inve
NEW YORK CITY, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" o
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.
10:48am, Friday, 29'th Nov 2024
The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
10:45am, Friday, 29'th Nov 2024
Applied Therapeutics (APLT) shares cratered Friday as the biopharmaceutical firm reported that the Food and Drug Administration (FDA) rejected its application for its experimental treatment for a rare
NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics"
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
05:59am, Friday, 29'th Nov 2024
On Wednesday, Applied Therapeutics, Inc APLT received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat for Classic Galactosemia.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
11:16am, Thursday, 28'th Nov 2024
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation
10:00am, Thursday, 28'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics"
US FDA declines to approve Applied Therapeutics' genetic disease drug
04:21pm, Wednesday, 27'th Nov 2024
The U.S. Food and Drug Administration on Wednesday declined to approve Applied Therapeutics' drug to treat galactosemia, a rare genetic metabolic disease, the company said.
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
04:10pm, Wednesday, 27'th Nov 2024
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced tha
Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know
01:05pm, Tuesday, 29'th Oct 2024
Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 29'th Oct 2024
Here is how Applied Therapeutics Inc. (APLT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year?
10:43am, Thursday, 10'th Oct 2024
Here is how Applied Therapeutics Inc. (APLT) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
10:46am, Tuesday, 24'th Sep 2024
Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy
01:02pm, Monday, 23'rd Sep 2024
Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
